🇧🇪 ARGX.BR — argenx SE

Salud Compra fuerte
← Volver

Precio actual

815,80 EUR

Máx. histórico

912,40

64 días

Caída desde máximo

-10,59%

Rango 52 semanas

568,40 – 925,00

Variación hoy

+0,03%

Cierre anterior

815,60

Rango de hoy

788,80 – 815,80

Volumen hoy

102.849

Peor caída histórica

-39,26%

21/07/2023 → 21/12/2023

Recuperado en 262 días

Volatilidad anualizada ⓘ

43,77%

Información
Nombre completo
argenx SE
Divisa
EUR
Mercado
Brussels
Sector
Salud
Industria
Biotechnology
Empleados
1.863
PER ⓘ
32,83 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
1.005,32 EUR (puede no estar actualizado)
Primera cotización
10/07/2014
Precio actualizado
hace 1 día
Sobre la empresa

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
13/02/2019 99,20 104,20 99,00 101,60 +3,36% 5,24% 117.938
12/02/2019 97,60 98,40 97,00 98,30 +1,76% 1,43% 35.334
11/02/2019 97,50 97,50 95,40 96,60 -0,92% 2,15% 58.490
08/02/2019 96,40 97,60 95,50 97,50 +1,04% 2,18% 60.541
07/02/2019 97,50 98,20 96,50 96,50 -0,82% 1,74% 52.539
06/02/2019 96,90 98,30 96,80 97,30 +0,10% 1,55% 52.336
05/02/2019 98,00 98,00 96,00 97,20 -0,92% 2,04% 79.698
04/02/2019 96,00 98,40 95,50 98,10 +4,58% 3,02% 123.383
01/02/2019 92,40 96,50 92,40 93,80 +1,41% 4,44% 89.356
31/01/2019 90,00 92,50 89,80 92,50 +3,70% 3,00% 65.513
30/01/2019 91,10 91,10 88,80 89,20 -2,41% 2,52% 55.357
29/01/2019 91,90 93,40 90,70 91,40 -0,98% 2,94% 41.269
28/01/2019 92,00 93,90 90,90 92,30 +0,22% 3,26% 89.424
25/01/2019 93,00 94,50 91,80 92,10 +0,55% 2,90% 57.709
24/01/2019 92,10 92,50 91,10 91,60 -0,33% 1,52% 66.834
23/01/2019 93,20 93,40 90,90 91,90 -0,86% 2,68% 77.560
22/01/2019 92,00 94,40 91,50 92,70 +0,98% 3,15% 337.652
21/01/2019 91,00 92,00 90,10 91,80 +2,00% 2,09% 55.173
18/01/2019 90,50 90,80 89,30 90,00 +0,78% 1,66% 99.839
17/01/2019 89,60 90,50 87,90 89,30 -0,22% 2,90% 87.602
16/01/2019 91,80 92,40 89,30 89,50 -1,76% 3,38% 100.434
15/01/2019 91,50 91,90 89,70 91,10 -0,44% 2,40% 127.416
14/01/2019 93,70 95,00 90,90 91,50 -2,35% 4,38% 94.914
11/01/2019 95,70 96,70 93,50 93,70 -1,99% 3,34% 87.925
10/01/2019 97,30 98,60 95,20 95,60 -2,75% 3,49% 74.494
09/01/2019 99,60 100,00 96,60 98,30 -0,10% 3,41% 73.380
08/01/2019 96,30 100,60 95,40 98,40 +0,41% 5,40% 214.237
07/01/2019 93,90 98,50 91,70 98,00 +5,72% 7,24% 168.624
04/01/2019 91,90 94,80 89,70 92,70 +4,51% 5,55% 178.834
03/01/2019 87,20 89,60 84,10 88,70 +2,42% 6,31% 86.919